



# Pfizer Inc. (PFE)

Updated February 7<sup>th</sup>, 2025 by Prakash Kolli

## Key Metrics

<b>Current Price:</b>	\$26	<b>5 Year CAGR Estimate:</b>	15.6%	<b>Market Cap:</b>	\$140.38B
<b>Fair Value Price:</b>	\$35	<b>5 Year Growth Estimate:</b>	5.0%	<b>Ex-Dividend Date:</b>	01/24/25
<b>% Fair Value:</b>	74%	<b>5 Year Valuation Multiple Estimate:</b>	6.1%	<b>Dividend Payment Date:</b>	03/07/25
<b>Dividend Yield:</b>	6.7%	<b>5 Year Price Target</b>	\$44	<b>Years Of Dividend Growth:</b>	16
<b>Dividend Risk Score:</b>	D	<b>Retirement Suitability Score:</b>	B	<b>Rating:</b>	Buy

## Overview & Current Events

Pfizer Inc. is a global pharmaceutical company focusing on prescription drugs and vaccines. Pfizer's CEO completed a series of transactions significantly altering the company structure and strategy. Pfizer formed the GSK Consumer Healthcare Joint Venture in 2019 with GlaxoSmithKline plc, which includes its over-the-counter business. Pfizer owns 32% of the JV, but is exiting the company, now known as Haleon. Pfizer spun off its Upjohn segment and merged it with Mylan forming Viatrix for its off patent, branded and generic medicines in 2020. Pfizer's top products are Eliquis, Plevnar family, Paxlovid, Comirnaty, Vyndaqel family, Ibrance, and Xtandi. Pfizer had revenue of \$63.6B in 2024.

Pfizer reported solid Q4 2024 results on February 4<sup>th</sup>, 2025. Companywide revenue grew 21% operationally to \$17,763M from \$14,570M and adjusted diluted earnings per share climbed to \$0.63 versus \$0.10 on a year-over-year basis because of stabilizing COVID-19 related sales, growing revenue from the existing portfolio, and lower expenses. Global Biopharmaceuticals sales gained 22% to \$17,413M from \$14,186M led by gains in Primary Care (+27%), Specialty Care (+12%), and Oncology (+27%). Pfizer Centerone saw 11% lower sales to \$325M, while Ignite revenue was \$26M. Of the top selling drugs, sales increased for Eliquis (+14%), Plevnar (-4%), Plaxlovid (flat), Comirnaty (-37%), Vyndaqel/Vyndamax (+61%), Ibrance (-2%), and Xtandi (+24%).

New launches, Octagam, Padcev, Adcetris, Tukysa, and Tivdak are growing rapidly.

Since 2021 the company has used its COVID cash flow to acquire companies like Trillium for its cancer drug candidates, Arena for its autoimmune candidate, ReViral for its RSV programs, biohaven for its CGRP assets (migraines), GBT for its sickle cell disease treatments, and Seagen for its ADC technology (oncology). We do not expect more large acquisitions.

Pfizer set revenue guidance at \$61.0B - \$64.0B and adjusted diluted EPS guidance at \$2.80 - \$2.90 in 2025.

## Growth on a Per-Share Basis

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
<b>EPS</b>	\$2.20	\$2.40	\$2.65	\$3.00	\$2.95	\$2.22	\$4.42	\$6.58	\$1.84	\$3.11	<b>\$2.90</b>	<b>\$3.70</b>
<b>DPS</b>	\$1.12	\$1.20	\$1.28	\$1.36	\$1.44	\$1.52	\$1.56	\$1.60	\$1.64	\$1.68	<b>\$1.72</b>	<b>\$1.81</b>
<b>Shares<sup>1</sup></b>	6175	6070	5979	5717	5534	5578	5623	5619	5647	5667	<b>5610</b>	<b>5336</b>

Pfizer's current product line is expected to produce top line and bottom-line growth out to 2030 because of significant R&D and acquisitions. As a result, Pfizer's current product line is growing. Previously declining volumes and sales of Paxlovid and Comirnaty have largely stabilized. Future growth will come from increasing sales for approved indications, extensions, R&D, bolt-on acquisitions, and margin expansion. Pfizer has a strong pipeline in oncology, inflammation & immunology, internal medicine, and vaccines and recently revamped its R&D leadership. However, loss of exclusivity (LOE) in Eliquis, Ibrance, and other drugs will cause a headwind between 2025 and 2028.

We are expecting 5% earnings per share growth out to 2030. We have reduced our dividend growth rate to 1% due to the spinoffs and higher debt, but this may be low. Pfizer is not focused on share repurchases. The company's capital allocation emphasis is strengthening the business, maintaining and growing the dividend, and de-levering in 2025.

<sup>1</sup> Share count in millions.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



# Pfizer Inc. (PFE)

Updated February 7<sup>th</sup>, 2025 by Prakash Kolli

## Valuation Analysis

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	Now	2030
Avg. P/E	14.7	13.5	13.7	14.6	13.3	29.5	10.7	9.5	14.0	8.5	<b>8.9</b>	<b>12.0</b>
Avg. Yld.	3.3%	3.7%	3.8%	3.5%	3.6%	4.1%	3.7%	3.2%	6.4%	6.3%	<b>6.7%</b>	<b>4.1%</b>

Pfizer's stock price is down since our last report despite beating estimates and improving operational execution. We have set our earnings estimate to the mid-point of 2025 guidance. Our fair value multiple is 12X, accounting for risks to an R&D pharma company. Pfizer's main business is performing well with new drug approvals and a robust pipeline from organic R&D and acquisitions. The current fair value is now \$35. Our 5-year price target is now \$44.

## Safety, Quality, Competitive Advantage, & Recession Resiliency

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
Payout	51%	50%	48%	45%	49%	68%	35%	24%	89%	54%	<b>59%</b>	<b>49%</b>


Pfizer is one of the largest pharmaceutical companies in the world. As such, it has scale in R&D, manufacturing, regulatory affairs, distribution, and marketing around the world. This gives Pfizer the ability to bring new therapies to market, partner with smaller companies, or acquire entire companies outright. The current pipeline is robust, and some will likely be blockbuster drugs even after attrition. As a pharmaceutical company, Pfizer is thought to be recession resistant. But there are always risks related to patent expiration, generics, competition, and regulatory approvals.

Debt has increased due to acquisitions, but Pfizer is de-levering. Short-term and current long-term debt are \$9,699M and long-term debt is \$58,002M offset by cash, equivalents, and marketable securities of \$9,952M at end of Q3 2024. Interest coverage is about 5.3X, and leverage ratio is 3.22X.

## Final Thoughts & Recommendation

At present we are forecasting 15.6% average annualized total return through 2030 from a dividend yield of 6.7%, 5.0% EPS growth, and 6.1% P/E multiple expansion. Declining COVID-related revenue has stabilized, and the therapies are still in demand. The travails of 2023 are mainly behind Pfizer. Pfizer's acquisitions have resulted in growing franchises with leadership in oncology. The firm is de-levering and the excellent dividend yield is backed by decent safety and commitment. Income investors should like this equity. We have maintained Pfizer's rating at a Buy.

## Total Return Breakdown by Year



Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



# Pfizer Inc. (PFE)

Updated February 7<sup>th</sup>, 2025 by Prakash Kolli

## Income Statement Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
<b>Revenue</b>	48851	52824	52546	53647	51750	41908	81288	100330	58496	63627
<b>Gross Profit</b>	39203	40502	41318	42399	41531	33216	50467	65986	33542	45776
<b>Gross Margin</b>	80.3%	76.7%	78.6%	79.0%	80.3%	79.3%	62.1%	65.8%	57.3%	71.9%
<b>SG&amp;A Exp.</b>	14809	14844	14804	14455	14350	11615	12703	13677	14771	14730
<b>D&amp;A Exp.</b>	5157	5757	6269	6384	6010	4777	5191	5064	6290	---
<b>Operating Profit</b>	12976	13710	14073	15045	13921	8760	20235	37272	3359	14938
<b>Op. Margin</b>	26.6%	26.0%	26.8%	28.0%	26.9%	20.9%	24.9%	37.1%	5.7%	23.5%
<b>Net Profit</b>	6960	7215	21308	11153	16273	9616	21979	31372	2119	8031
<b>Net Margin</b>	14.2%	13.7%	40.6%	20.8%	31.4%	22.9%	27.0%	31.3%	3.6%	12.6%
<b>Free Cash Flow</b>	13192	14193	14585	13631	9994	11612	29869	26031	4793	---
<b>Income Tax</b>	1990	1123	-9049	706	1384	477	1852	3328	-1115	-28

## Balance Sheet Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
<b>Total Assets (\$B)</b>	167.4	171.6	171.8	159.4	167.5	154.2	181.5	197.2	226.5	---
<b>Cash &amp; Equivalents</b>	3641	2595	1342	1139	1305	1784	1944	416	2853	---
<b>Acc. Receivable</b>	8176	8225	8221	8025	8724	7930	11479	10952	11177	---
<b>Inventories</b>	7513	6783	7578	7508	8283	8046	9059	8981	10189	---
<b>Goodwill (\$B)</b>	88.6	107.1	104.7	88.6	94.0	78.0	74.4	94.7	132.7	---
<b>Total Liab. (\$B)</b>	102.4	111.8	100.1	95.7	104.0	907.6	104.0	101.3	137.2	---
<b>Accounts Payable</b>	3620	4536	4656	4674	4220	4309	5578	6809	6710	---
<b>Long-Term Debt</b>	38899	42085	43492	41740	52150	38274	36998	34870	70845	---
<b>Total Equity</b>	64694	59520	71287	63388	63126	63238	77201	95661	89014	---
<b>D/E Ratio</b>	0.60	0.71	0.61	0.66	0.83	0.61	0.48	0.36	0.80	---

## Profitability & Per Share Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
<b>Return on Assets</b>	4.2%	4.3%	12.4%	6.7%	10.0%	6.0%	13.1%	16.6%	1.0%	---
<b>Return on Equity</b>	10.2%	11.6%	32.6%	16.6%	25.7%	15.2%	31.3%	36.3%	2.3%	---
<b>ROIC</b>	6.6%	7.0%	19.6%	10.1%	14.7%	8.9%	20.3%	25.6%	1.5%	---
<b>Shares Out.</b>	6175	6070	5979	5977	5675	5479	5708	5733	5643	5700
<b>Revenue/Share</b>	7.81	8.58	8.67	8.98	9.12	7.44	14.2	17.5	10.37	11.16
<b>FCF/Share</b>	2.11	2.30	2.41	2.28	1.76	2.06	5.23	4.54	0.85	---

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

### Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.